Clinical Trials Directory

Trials / Completed

CompletedNCT02765464

Acute Kidney Injury in Critically Ill Patients

Predicting Acute Kidney Injury in Critically Ill Trauma Patients Using Metalloproteinase 2 (TIMP2) and Insulin-like Growth Factor Binding Protein7 (IGFBP 7)

Status
Completed
Phase
Study type
Observational
Enrollment
50 (actual)
Sponsor
Loma Linda University · Academic / Other
Sex
All
Age
21 Years
Healthy volunteers
Not accepted

Summary

Acute kidney injury (AKI) in critically ill trauma patients has been shown to significantly increase mortality, length of stay, and costs, however detection has proven difficult as markers like elevated creatinine and decreased urine output may take days to manifest and are late indicators of AKI. The combination of two urinary biomarkers, Tissue Inhibitor of Metalloproteinase 2 (TIMP-2) and Insulin-like Growth Factor Binding Protein 7 (IGFBP-7), has been shown to increase within 12 hours following renal insult, allowing assessment of risk for developing acute kidney injury. Therefore, the investigators plan to assess if acute kidney injury in critically ill trauma patients can be determined earlier using urinary TIMP-2 and IGFBP-7 via the NephroCheck testing system. These markers have not been specifically evaluated in trauma patients at risk of AKI.

Conditions

Timeline

Start date
2016-10-01
Primary completion
2019-11-30
Completion
2019-11-30
First posted
2016-05-06
Last updated
2021-10-26

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT02765464. Inclusion in this directory is not an endorsement.